Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Gilead Sciences is conducting a Phase 1/2 clinical study titled A Phase 1/2, Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer. The study aims to evaluate the safety, tolerability, and efficacy of sacituzumab govitecan-hziy (SG) in treating advanced triple-negative breast cancer (TNBC), focusing on objective response rate and progression-free survival.
Intervention/Treatment: The study tests sacituzumab govitecan-hziy (SG), an intravenous drug, administered at an alternative dose and schedule to assess its effectiveness in TNBC patients.
Study Design: This interventional study is non-randomized and follows a sequential model with no masking. It is primarily focused on treatment, with participants receiving SG until disease progression, death, or unacceptable toxicity occurs.
Study Timeline: The study began on April 30, 2025, with the latest update submitted on July 15, 2025. These dates are crucial as they mark the study’s progression and the availability of updated information for stakeholders.
Market Implications: The ongoing study could influence Gilead Sciences’ stock performance positively if results show favorable outcomes, enhancing investor confidence. This study positions Gilead in a competitive landscape, potentially impacting its market share in oncology treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.